Skip to content

Study · Non-randomized trial · n = 10 · 1989

3 results

DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.

Cattaneo M, Moia M, Delle Valle P, Castellana P, Mannucci PM

Blood1 Nov 1989Cited by 45 (Europe PMC)

PMID2508791 (opens in a new tab)DOI10.1182/blood.v74.6.1972.1972 (opens in a new tab)PepBankPUB-02508791
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In severe von Willebrand disease, DDAVP after cryoprecipitate shortened bleeding time to 9 +/- 2 minutes versus 15 +/- 3 with saline.

    In plain wordsIn severe von Willebrand disease, DDAVP after cryoprecipitate shortened bleeding time compared with saline.

    Peptide
    Desmopressin
    Outcome
    DecreaseBleeding time
    Study

    n = 10

    Comparator
    Saline after cryoprecipitate
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · intravenousAs given in this study (human).

    Measurements

    Bleeding time
    > 30 minutes
    before cryoprecipitate, very prolonged
    Bleeding time
    14 minutes
    after cryoprecipitate, before DDAVP or saline, +/- 2 SEM
    Bleeding time
    9 minutes
    after DDAVP following cryoprecipitate, +/- 2 SEM
    Bleeding time
    15 minutes
    after saline following cryoprecipitate, +/- 3 SEM; reported as ns
    p
    < 0.01
    DDAVP shortening after cryoprecipitate, as reported

    Source sentences

    Summary
    Their very prolonged bleeding times (greater than 30 minutes), partially corrected by the infusion of cryoprecipitate (14 +/- 2 minutes, mean +/- SEM), were further shortened by the administration of DDAVP (9 +/- 2 minutes, P less than .01) but not of saline (15 +/- 3 minutes, ns).
    1 context sentence
    Summary · context
    Since DDAVP shortens the bleeding time in a variety of bleeding disorders, we investigated in a double-blind, placebo-controlled crossover study the effects of the intravenous (IV) infusion of DDAVP (0.3 microgram/kg) on the bleeding times of 10 patients with severe vWD treated with cryoprecipitate.
  2. 02HumanNon-randomized trialMechanism

    In severe von Willebrand disease, plasma vWF levels did not change after DDAVP following cryoprecipitate.

    In plain wordsIn severe von Willebrand disease, DDAVP did not change plasma vWF after cryoprecipitate.

    Peptide
    Desmopressin
    Outcome
    No significant changePlasma vWF
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Plasma vWF levels, raised from unmeasurable to normal values by cryoprecipitate, were not changed after DDAVP or saline.
    1 context sentence
    Summary · context
    Since DDAVP shortens the bleeding time in a variety of bleeding disorders, we investigated in a double-blind, placebo-controlled crossover study the effects of the intravenous (IV) infusion of DDAVP (0.3 microgram/kg) on the bleeding times of 10 patients with severe vWD treated with cryoprecipitate.
  3. 03HumanNon-randomized trialMechanism

    In severe von Willebrand disease, DDAVP did not significantly affect platelet deposition after cryoprecipitate.

    In plain wordsIn severe von Willebrand disease, DDAVP did not significantly change platelet deposition after cryoprecipitate.

    Peptide
    Desmopressin
    Outcome
    No significant changePlatelet deposition
    Study

    n = 8

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The defective deposition of platelets from eight patients onto human umbilical artery subendothelium was increased but not normalized by cryoprecipitate and was not significantly affected by DDAVP or saline.
    1 context sentence
    Summary · context
    Since DDAVP shortens the bleeding time in a variety of bleeding disorders, we investigated in a double-blind, placebo-controlled crossover study the effects of the intravenous (IV) infusion of DDAVP (0.3 microgram/kg) on the bleeding times of 10 patients with severe vWD treated with cryoprecipitate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.